Vaxcyte, Inc. (PCVX)
Fuera de horario:
Vaxcyte, Inc.
825 Industrial Road
Suite 300
San Carlos, CA 94070
United States
650 837 0111
https://vaxcyte.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 254
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director | 1.13M | 1.2M | 1968 |
| Mr. Andrew L. Guggenhime M.B.A. | President & CFO | 820.81k | 1.9M | 1968 |
| Mr. James Wassil M.B.A., M.S. | Executive VP & COO | 521.05k | 943.62k | 1969 |
| Mr. Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 684.62k | 930.64k | 1982 |
| Dr. Ashish Khanna M.B.A., Ph.D. | Co-Founder | N/D | N/D | 1972 |
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research | N/D | N/D | 1964 |
| Ms. Elvia Cowan | Senior VP of Finance & Principal Accounting Officer | N/D | N/D | 1973 |
| Ms. Janet Graesser | Senior Vice President of Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Ms. Whitney Jones | Chief People Officer | N/D | N/D | N/D |
| Mr. Paul W. Sauer M.B.A. | Senior Vice President of Process Development & Manufacturing | 608.96k | N/D | 1961 |
Descripción
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Vaxcyte, Inc. a partir del 1 de octubre de 2024 es 7. Las puntuaciones principales son Auditoría: 2; Junta: 5; Derechos del accionista: 8; Compensación: 9.
